CD274 and neoplasm: The expression of PD-L1 in certain tumor types is a predictive factor of response to anti-PD-1 or anti-PD-L1 therapy; 88% of newly diagnosed glioblastoma and 72% of relapsed glioblastoma show PD-L1 overexpression, although generally at a low level [80].